Physician profile
Yan Yan
NPI 1154663771
$3,630.40
in general payments reported to CMS, 2019-2025
24 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $963 · 2021: $248 · 2022: $77.18 · 2023: $138 · 2024: $415 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.36 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $657.32 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $525.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $437.87 | 2019-2025 | Tezspire, Fasenra |
| Aimmune Therapeutics, INC. | $350.00 | 2020 | |
| Optinose US, INC. | $270.27 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $167.18 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.82 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $137.37 | 2022-2025 | |
| Organon LLC | $113.91 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $98.52 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $89.03 | 2025 | |
| Amgen INC. | $79.90 | 2025 | Tezspire |
| Covis Pharma Gmbh | $78.30 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.00 | 2025 | Cuvitru |
| Lilly USA, LLC | $60.46 | 2025 | Ebglyss, Taltz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $58.07 | 2020 | |
| Incyte Corporation | $54.33 | 2025 | Opzelura |
| Octapharma USA, INC. | $48.52 | 2019 | |
| Leo Pharma INC. | $47.93 | 2025 | Anzupgo |
| Ars Pharmaceuticals Operations, INC. | $41.68 | 2025 | Neffy |
| Arcutis Biotherapeutics, INC. | $37.09 | 2025 | Zoryve |
| Csl Behring | $25.25 | 2020 | |
| Biocryst US Sales Co., LLC | $20.14 | 2025 | Orladeyo |
| Pfizer INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.